NNNN Anbio Biotechnology
$3.30
▲ 0.0%Updated Oct 16, 2:25 PM ET
Report Card
NNNN at a glance — five pillars scored 0–100 from real filed financials.
How the 0–100 rating is calculatedOverall: not rated yet. This stock's fundamentals ratios aren't loaded, so only the pillars its filings support are scored.
Key Metrics
Market Cap
—
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
15.0%
Interest Coverage
—
Current Ratio
344.31x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
Not rated
Business Overview
Anbio Biotechnology (NNNN) is a NASDAQ-listed company in the Biotechnology industry, within the Health Care sector.
In its latest reported year it generated about $8.65M in revenue and $6.40M in net profit.
Our model hasn't rated NNNN yet because its fundamentals ratios (P/E, margins, returns on capital, leverage) aren't loaded. Any financial history below comes straight from its SEC filings and refreshes automatically.
Revenue Growth
3Y CAGR
-28.4%
Revenue moved from $23.54M in 2022 to $8.65M in 2025, a -28.4% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Profitability
Gross Margin
87.2%
Operating Margin
66.7%
Net Margin
74.1%
ROE
—
Debt Analysis
Total Debt
—
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
—
Leverage: debt-to-equity is n/a, with a current ratio of 344.3x. Detailed balance-sheet leverage is limited for this name.
Cash Flow Analysis
Operating CF
-$6.74M
Free Cash Flow
-$6.74M
FCF Margin
-77.9%
In the latest year Anbio Biotechnology produced about -$6.74M of operating cash flow but negative free cash flow as it invested heavily. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Valuation Analysis
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
NNNN trades at n/a trailing earnings. Its valuation ratios aren't loaded yet, so there is no P/E to judge here.
Metrics vs. Sector Range
Where NNNN sits versus the Health Care companies we cover.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
Sector Peer Comparison
How NNNN stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
NNNN doesn't have a model rating yet (its fundamentals ratios aren't loaded), so it isn't ranked against the 83 rated Health Care companies we cover.
P/E vs sector
—
median 26.1x
ROE vs sector
—
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
—
not rated yet
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.
Key Risks
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
Latest SEC Filings
NNNN's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K
NNNN — frequently asked questions
Is NNNN a good stock to buy?
We don't give buy or sell advice. Review Anbio Biotechnology's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does NNNN's data come from?
Live price data plus the annual financials in Anbio Biotechnology's SEC filings, refreshed automatically. Its fundamentals ratios aren't loaded yet, which is why it has no model rating.
How is the 5-year projection for NNNN calculated?
It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.
Is this NNNN analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell NNNN. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.